Breaking News – Another Treatment Option Approved for MPNs
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
Pacritinib a novel JAK2/FLT3 and IRAK inhibitor has been approved for MF patients with low platelets and we hope it will be widely available soon with hopefully more global approvals to follow.
VONJO (pacritinib) has been approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.
Read the full news release here.
